Want to see XTNT full AI Analyst Report?
XTNT Stock Chart & Stats
$0.33
$0.01(2.61%)
At close: 4:00 PM EDT
$0.33
$0.01(2.61%)
Day’s Range― - ―
52-Week Range$0.27 - $0.95
Previous Close$0.44
Volume19.38K
Average Volume (3M)171.31K
Market Cap
$38.59M
Enterprise Value$74.84M
Total Cash (Recent Filing)$9.87M
Total Debt (Recent Filing)$26.01M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 06, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding140,287,960
10 Day Avg. Volume101,784
30 Day Avg. Volume171,308
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.15
Price to Sales (P/S)0.82
P/FCF Ratio10.76
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue0.68
Enterprise Value/Gross Profit1.15
Enterprise Value/Ebitda-30.50
Forecast
1Y Price Target
$1.03Price Target Upside213.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.03
Revenue Forecast (FY)$99.44M
Bulls Say, Bears Say
Bulls Say
Solid Gross MarginConsistently solid gross margins indicate that Xtant’s biologics and spine products retain meaningful underlying economics. If procedure volumes and product mix stabilize, this margin base can support reinvestment, commercial expansion, and eventual operating leverage.
Improved Balance SheetImproved leverage and a sizable positive equity base provide a stronger financial cushion than in prior periods. This supports continued investment in products and sales coverage while reducing, though not eliminating, the balance-sheet pressure created by earnings volatility.
Expanded Commercial PlatformThe Dilon integration materially expands sales coverage, hospital access, and cross-selling potential across Xtant’s biologics portfolio. A larger commercial organization, combined with HEMOBLAST and new product traction, could create a more durable platform for institutional adoption and revenue growth.
Bears Say
Revenue ContractionThe sharp quarterly decline and lower annual outlook show that asset changes, license cessation, and biologics weakness are weighing on the current revenue base. Persistent contraction would reduce operating leverage and make the expanded sales platform slower to translate into sustainable growth.
Margin And Profitability PressureThe steep margin compression and swing to negative adjusted EBITDA indicate that weaker volume, lower production efficiency, inventory charges, and strategic spending are currently overwhelming the company’s gross-profit base. Continued pressure would delay a reliable return to profitable growth.
Weak Cash Generation And LiquidityNegative or inconsistent free cash flow reduces Xtant’s ability to fund commercial expansion internally and leaves less room for operating setbacks. Lower cash and limited revolver availability increase dependence on improved execution, working-capital control, and a recovery in earnings.
XTNT FAQ
What was Xtant Medical Holdings’s price range in the past 12 months?
Xtant Medical Holdings lowest stock price was $0.27 and its highest was $0.95 in the past 12 months.
What is Xtant Medical Holdings’s market cap?
Xtant Medical Holdings’s market cap is $38.59M.
When is Xtant Medical Holdings’s upcoming earnings report date?
Xtant Medical Holdings’s upcoming earnings report date is Nov 06, 2026 which is in 9 days.
How were Xtant Medical Holdings’s earnings last quarter?
Xtant Medical Holdings released its earnings results on Aug 11, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.05.
Is Xtant Medical Holdings overvalued?
According to Wall Street analysts Xtant Medical Holdings’s price is currently Undervalued.
Does Xtant Medical Holdings pay dividends?
Xtant Medical Holdings does not currently pay dividends.
What is Xtant Medical Holdings’s EPS estimate?
Xtant Medical Holdings’s EPS estimate is -0.03.
How many shares outstanding does Xtant Medical Holdings have?
Xtant Medical Holdings has 140,287,960 shares outstanding.
What happened to Xtant Medical Holdings’s price movement after its last earnings report?
Xtant Medical Holdings reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -28.251%.
Which hedge fund is a major shareholder of Xtant Medical Holdings?
Currently, no hedge funds are holding shares in XTNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xtant Medical Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.03 (213.13% Upside)
$1.03 (213.13% Upside)
Blogger Sentiment
Bullish
XTNT Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.66%
12-Months-Change
Fundamentals
Return on Equity
-23.45%
Trailing 12-Months
Asset Growth
-23.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xtant Medical Holdings
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
XTNT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.View all XTNT earnings summariesXTNT Stock 12 Month Forecast
Average Price Target
$1.03
▲(213.13% Upside)
Technical Analysis
Integra Lifesciences
―
Orthofix Medical
―
Stryker
―
Zimmer Biomet Holdings
―
Bioventus
―
Ownership Overview
12.05% Insiders
1.84% Mutual Funds
0.33% Other Institutional Investors
84.30% Public Companies and
Individual Investors









